The company beat analyst earnings estimates in the second quarter, ended June with $1.1 billion in cash and investments, and is preparing multiple 2H 2026 data readouts and European launches.
Krystal Biotech reported second-quarter 2026 global VYJUVEK revenue of $119.2 million, up 24% year over year, as sales of the dystrophic epidermolysis bullosa gene therapy continued to expand in the United States and overseas. The company posted net income of $54.8 million, or $1.85 a share basic and $1.79 diluted, with diluted earnings per share above analyst estimates and up from $1.29 a year earlier. Gross margin was 95%, and cash, cash equivalents and investments totaled $1.1 billion at June 30, 2026. For the first half, product revenue reached $235.6 million and net income was $110.7 million, or $3.76 a share basic and $3.62 diluted. Krystal said VYJUVEK remains on track for launches in Spain and Italy later this year, with pricing discussions continuing in Germany, France and the UK and additional filings planned for Switzerland and Australia in 2H 2026. The company also outlined several expected clinical and regulatory milestones across ophthalmology, respiratory disease, dermatology and oncology, including programs KB803, KB801, KB407, KB408, KB111 and KB707.